Study 123ABC 
==============

***The schedule and checklists for the study.***

**Author:** *Mike Vogel CRC Manager*

# Schedule


## Study Timeline Table
| Visit Name              | Alternative Name | Phase     | Window (-) | Day/Date | Window (+) |
| :---------------------- | :--------------- | :-------- | :--------- | :------- | :--------- |
| ICF (1A)                |                  | Screening | 0          | -56      | 0          |
| Screening (1B/1C)       |                  | Screening | 1          | -55      | 1          |
| BAE (2A)                |                  | Screening | 0          | -20      | 0          |
| BAE (2B)                |                  | Screening | 0          | -6       | 6          |
| Randomization (3A)      |                  | Treatment | 0          | 1        | 0          |
| Dose Admin (3A)         |                  | Treatment | 2          | 29       | 2          |
| Dose Admin (3B)         |                  | Treatment | 2          | 57       | 2          |
| Dose Admin (3C)         |                  | Treatment | 2          | 85       | 2          |
| Dose Admin (3D)         |                  | Treatment | 2          | 113      | 2          |
| Dose Admin (3E)         |                  | Treatment | 2          | 141      | 2          |
| PAC1 (4A)               |                  | Treatment | 2          | 169      | 2          |
| Dose admin/PAC1 (3F/4B) |                  | Treatment | 2          | 197      | 2          |
| Dose admin/PAC1 (3G/4C) |                  | Treatment | 2          | 197      | 2          |
| Dose admin/PAC1 (3G/4C) |                  | Treatment | 2          | 197      | 2          |
| Dose admin/PAC1 (3H/4D) |                  | Treatment | 2          | 197      | 2          |
| Dose Admin (3G)         |                  | Treatment | 2          | 225      | 2          |
| Dose Admin (3H)         |                  | Treatment | 2          | 253      | 2          |
| End of dose (3I)        |                  | Treatment | 2          | 281      | 2          |
| PAC2 (4C)               |                  | Treatment | 2          | 316      | 2          |
| PAC2 (4D)               |                  | Treatment | 2          | 330      | 2          |
| PAC3 (4E)               |                  | Treatment | 2          | 407      | 2          |
| PAC3 (4F)               |                  | Treatment | 2          | 421      | 2          |
| Follow up (5)           |                  | Treatment | 5          | 421      | 5          |



## Chart

[View the interactive chart of the schedule](../timeline.html)

---

# Checklist

Task: Informed Consent
The purpose of this task is to obtain informed consent from the patient. This will involve discussing the study with them, then an internal medical discussion to determine their eligibility to move forward.

Collapse all

Step 1 - Obtain Informed Consent
Details
Explain the study details, including purpose, procedures, risks, and benefits to the patient
Obtain informed consent from the patient, ensuring they understand and agree to the study terms
[Optional] Discuss with the patient about the possibility of using their data for future research
REFERENCES
Protocol - Consent Definition
link
Protocol - Inclusion/Exclusion Criteria
link
Consent Form
link
Guidance on Research Use of Data
link
PEOPLE
Patricia Bellweather
(Patient Recruiter)
email
pbellweather@mail.com
phone509.555.3419

Step 2 - Record Consent Decision
Details
File the signed consent form in the patients clinical study folder
Scan the signed consent form into the EHR system
Record the signed consent into the EDC system
REFERENCES
Record Keeping Guidelines
link
Epic EHR
link
linkRobot Script Available
Medidata EDC
link
linkRobot Script Available

Step 3 - Inform Internal Medical Personnel
Details
Email Patricia with the result of the consent
Inform Rachel and Mark about the patient consent
PEOPLE
Patricia Bellweather
(Patient Recruiter)
email
pbellweather@mail.com
phone509.555.3419
Rachel Auchliffe
(Site Rater)
email
rauchliffe@mail.com
phone957.555.2323
Mark Davis
(Clinical Trial Administrator)
email
mdavis@mail.com
---